0 XP   0   0   0

Enzon Pharmaceuticals Inc
Buy or Sell?

Welcome Invester! I guess you are interested in Enzon Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's start. I'm going to help you getting a better view of Enzon Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Enzon Pharmaceuticals Inc even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Enzon Pharmaceuticals Inc is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Enzon Pharmaceuticals Inc. The closing price on 2022-09-27 was $0.25 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Enzon Pharmaceuticals Inc Daily Candlestick Chart


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficiently in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-erm debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

1.1. Profitability of Enzon Pharmaceuticals Inc.

1.1. Profitability

An important factor of a company's health is the profitability.

1.1.1. Net Profit Margin
  • Measures how much profit a company generates for each dollar of revenue.
  • Above 10% is considered healthy depending on the industry.
  • A net profit margin of 25% means that $0,25 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Enzon Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-202.6%+202.6%
TTM-202.6%YOY-1,586.0%+1,383.4%
TTM-202.6%5Y-1,837.6%+1,635.0%
5Y-1,837.6%10Y-897.8%-939.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--241.1%+241.1%
TTM-202.6%-275.9%+73.3%
YOY-1,586.0%-332.0%-1,254.0%
5Y-1,837.6%-473.7%-1,363.9%
10Y-897.8%-560.4%-337.4%
1.1.2. Return on Assets
  • Shows how profitable a company is in relation to its total assets.
  • Above 5% is considered healthy depending on the industry.
  • 5% return on assets means the company generated $0,05 for each $1 in assets.

Let's take a look of the Return on Assets trends of Enzon Pharmaceuticals Inc:

  • The MRQ is -0.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -0.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.5%TTM-0.5%+0.1%
TTM-0.5%YOY-2.0%+1.5%
TTM-0.5%5Y0.6%-1.1%
5Y0.6%10Y8.8%-8.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.5%-9.8%+9.3%
TTM-0.5%-8.8%+8.3%
YOY-2.0%-9.2%+7.2%
5Y0.6%-11.6%+12.2%
10Y8.8%-12.6%+21.4%
1.1.3. Return On Equity
  • Measures the profit in relation to shareholders equity (total assets - total liabilities).
  • Above 15%-20% is considered healthy depending on the industry
  • 10% return on equity means the company generated $0,1 for each $1 the owners (shareholders) invested.

Let's take a look of the Return On Equity trends of Enzon Pharmaceuticals Inc:

  • The MRQ is -0.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.5%TTM-4.1%+3.7%
TTM-4.1%YOY-2.2%-1.9%
TTM-4.1%5Y-0.3%-3.8%
5Y-0.3%10Y10.1%-10.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.5%-11.9%+11.4%
TTM-4.1%-11.1%+7.0%
YOY-2.2%-10.7%+8.5%
5Y-0.3%-13.7%+13.4%
10Y10.1%-14.5%+24.6%

1.2. Operating Efficiency of Enzon Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin
  • Measures how much profit a company makes for each $1 of sales after paying variable costs (production costs, wages) but before taxes.
  • Above 15% is considered healthy depending on the industry
  • An operating margin of 20% means the company generated $0,2 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Enzon Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-199.1%+199.1%
TTM-199.1%YOY-1,582.2%+1,383.1%
TTM-199.1%5Y-2,149.1%+1,949.9%
5Y-2,149.1%10Y-1,041.4%-1,107.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--232.1%+232.1%
TTM-199.1%-269.6%+70.5%
YOY-1,582.2%-307.6%-1,274.6%
5Y-2,149.1%-472.5%-1,676.6%
10Y-1,041.4%-572.5%-468.9%
1.2.2. Operating Ratio
  • Measures how efficient the company is creating its products or services while keeping operating costs low.
  • Below 1 is considered healthy depending on the industry
  • An operation ratio of 0.5 means that the operating costs are $0,5 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Enzon Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2.241-2.241
TTM2.241YOY16.833-14.591
TTM2.2415Y25.046-22.805
5Y25.04610Y12.707+12.340
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.321-3.321
TTM2.2413.614-1.373
YOY16.8333.573+13.260
5Y25.0465.754+19.292
10Y12.7077.024+5.683

1.3. Liquidity of Enzon Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio
  • Measures if the company is able to pay off short-term debts (debts due within 1 year).
  • Above 1.5 is considered healthy depending on the industry.
  • A current ratio of 1.5 means the company has $1.5 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Enzon Pharmaceuticals Inc:

  • The MRQ is 125.263. The company is very able to pay all its short-erm debts. +2
  • The TTM is 121.691. The company is very able to pay all its short-erm debts. +2
Trends
Current periodCompared to+/- 
MRQ125.263TTM121.691+3.572
TTM121.691YOY85.473+36.217
TTM121.6915Y51.687+70.003
5Y51.68710Y36.812+14.876
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ125.2635.298+119.965
TTM121.6916.208+115.483
YOY85.4736.369+79.104
5Y51.6876.753+44.934
10Y36.8126.512+30.300
1.3.2. Quick Ratio
  • Measures if the company is able to pay short-term debts (debts due within 1 year). But only uses the most liquid assets (assets that can be sold/used right now like cash).
  • Above 1 is considered healthy depending on the industry.
  • A quick ratio of 0,8 means the company can pay off $0,8 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Enzon Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.017-0.017
TTM0.017YOY85.188-85.171
TTM0.0175Y25.294-25.276
5Y25.29410Y27.861-2.567
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.068-4.068
TTM0.0174.975-4.958
YOY85.1885.250+79.938
5Y25.2945.323+19.971
10Y27.8615.034+22.827

1.4. Solvency of Enzon Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt To Asset Ratio
  • Shows if the company is owned by creditors or shareholders.
  • Below 1 (100%) is considered healthy depending on the industry
  • A debt to asset ratio of 0.45 (45%) means that the company is financed with 45% credit and 55% is financed by it's owners (shareholders).

Let's take a look of the Debt To Asset Ratio trends of Enzon Pharmaceuticals Inc:

  • The MRQ is 0.008. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.676. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.008TTM0.676-0.668
TTM0.676YOY0.035+0.641
TTM0.6765Y0.194+0.482
5Y0.19410Y0.190+0.004
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0080.269-0.261
TTM0.6760.267+0.409
YOY0.0350.295-0.260
5Y0.1940.360-0.166
10Y0.1900.396-0.206
1.4.2. Debt to Equity Ratio
  • Measures the total debt versus the total shareholders equity (total assets - total liabilities).
  • Below 2 is considered healthy depending on the industry.
  • A debt to equity ratio of 0.84 means that company has $0,84 debt for each $1 in equity.

Let's take a look of the Debt to Equity Ratio trends of Enzon Pharmaceuticals Inc:

  • The MRQ is 0.008. The company is very able to pay all its debts with equity. +2
  • The TTM is 6.776. The company is just not able to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ0.008TTM6.776-6.768
TTM6.776YOY0.038+6.737
TTM6.7765Y1.438+5.337
5Y1.43810Y0.892+0.547
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0080.306-0.298
TTM6.7760.304+6.472
YOY0.0380.306-0.268
5Y1.4380.379+1.059
10Y0.8920.435+0.457

2. Market Valuation of Enzon Pharmaceuticals Inc

2. Earnings
2.1. Price to Earnings Ratio
  • Compares the company's stock price to its earnings.
  • Above 15 is considered overpriced but is hard to determine (always use industry average).
  • A PE ratio of 15 means the investor is paying $15 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Enzon Pharmaceuticals Inc:

  • The EOD is -6.107. Company is losing money. -2
  • The MRQ is -7.573. Company is losing money. -2
  • The TTM is -9.072. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-6.107MRQ-7.573+1.466
MRQ-7.573TTM-9.072+1.499
TTM-9.072YOY-14.529+5.457
TTM-9.0725Y1.078-10.150
5Y1.07810Y5.204-4.126
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.107-2.142-3.965
MRQ-7.573-2.296-5.277
TTM-9.072-3.837-5.235
YOY-14.529-5.042-9.487
5Y1.078-3.664+4.742
10Y5.204-3.328+8.532
2.2. Price Earnings to Growth Ratio
  • Measures how expensive or cheap the stock is compared to its predicted growth
  • Lower is better
  • A PEG ratio of 1 means the investor is paying a fair price for the stock

Let's take a look of the Price Earnings to Growth Ratio trends of Enzon Pharmaceuticals Inc:

  • The MRQ is -0.437. Very Bad. -2
  • The TTM is -0.815. Very Bad. -2
Trends
Current periodCompared to+/- 
MRQ-0.437TTM-0.815+0.378
TTM-0.815YOY-0.219-0.596
TTM-0.8155Y-0.257-0.558
5Y-0.25710Y-0.165-0.091
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.4370.005-0.442
TTM-0.8150.020-0.835
YOY-0.2190.040-0.259
5Y-0.2570.021-0.278
10Y-0.1650.017-0.182

2. Books
2.3. Price to Book Ratio
  • Shows if the stock is under or overvalued compared to it's book value (total assets - total liabilities).
  • At or below 1 is considered healthy
  • A PB ratio of 3 means the investor is paying $3 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Enzon Pharmaceuticals Inc:

  • The EOD is 0.396. Very good. +2
  • The MRQ is 0.491. Very good. +2
  • The TTM is 4.052. Neutral. Compare to industry.
Trends
Current periodCompared to+/- 
EOD0.396MRQ0.491-0.095
MRQ0.491TTM4.052-3.560
TTM4.052YOY1.052+2.999
TTM4.0525Y1.774+2.277
5Y1.77410Y2.165-0.391
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.3961.796-1.400
MRQ0.4911.953-1.462
TTM4.0522.778+1.274
YOY1.0523.538-2.486
5Y1.7742.761-0.987
10Y2.1652.410-0.245

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Enzon Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Per Share--0.6310.207+205%0.513+23%0.264+139%0.486+30%
Current Ratio--125.263121.691+3%85.473+47%51.687+142%36.812+240%
Debt To Asset Ratio--0.0080.676-99%0.035-77%0.194-96%0.190-96%
Debt To Equity Ratio--0.0086.776-100%0.038-79%1.438-99%0.892-99%
Eps---0.010-0.010+2%-0.009-13%0.002-636%0.041-125%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin----2.0260%-15.8600%-18.3760%-8.9780%
Operating Margin----1.9910%-15.8220%-21.4910%-10.4140%
Operating Ratio---2.241-100%16.833-100%25.046-100%12.707-100%
Pb Ratio0.396-24%0.4914.052-88%1.052-53%1.774-72%2.165-77%
Pe Ratio-6.107+19%-7.573-9.072+20%-14.529+92%1.078-802%5.204-246%
Peg Ratio---0.437-0.815+87%-0.219-50%-0.257-41%-0.165-62%
Price Per Share0.250-24%0.3100.333-7%0.475-35%0.303+2%0.911-66%
Quick Ratio---0.017-100%85.188-100%25.294-100%27.861-100%
Return On Assets---0.005-0.005+12%-0.020+337%0.006-177%0.088-105%
Return On Equity---0.005-0.041+807%-0.022+383%-0.003-34%0.101-104%
 EOD+2 -1MRQTTM+10 -3YOY+10 -35Y+8 -510Y+9 -4

3.2. Fundamental Score

Let's check the fundamental score of Enzon Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.107
Price to Book Ratio (EOD)Between0-10.396
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than1125.263
Debt To Asset Ratio (MRQ)Less than10.008
Debt to Equity Ratio (MRQ)Less than10.008
Return On Equity (MRQ)Greater than0.15-0.005
Return on Assets (MRQ)Greater than0.05-0.005
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Enzon Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.260
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2022-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets47,224
Total Liabilities377
Total Stockholder Equity46,847
 As reported
Total Liabilities 377
Total Stockholder Equity+ 46,847
Total Assets = 47,224

Assets

Total Assets47,224
Total Current Assets47,224
Long-term Assets47,224
Total Current Assets
Cash And Cash Equivalents 46,794
Other Current Assets 430
Total Current Assets  (as reported)47,224
Total Current Assets  (calculated)47,224
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities377
Long-term Liabilities0
Total Stockholder Equity46,847
Total Current Liabilities
Accounts payable 331
Total Current Liabilities  (as reported)377
Total Current Liabilities  (calculated)331
+/- 46
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock742
Total Stockholder Equity (as reported)46,847
Total Stockholder Equity (calculated)742
+/- 46,105
Other
Capital Stock44,287
Common Stock Shares Outstanding 74,215
Net Invested Capital 3,302
Net Tangible Assets 3,302
Net Working Capital 46,847



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-31
> Total Assets 
136,528
130,252
135,792
135,182
143,690
549,676
557,426
572,543
578,721
610,747
620,375
633,912
623,787
728,566
728,124
738,397
738,693
722,410
719,223
722,584
716,628
650,861
356,816
516,119
384,375
403,830
368,809
355,431
423,518
420,357
357,889
364,865
353,350
349,253
331,906
331,094
337,675
332,749
533,142
535,790
515,080
488,857
444,843
386,699
354,538
343,209
336,946
317,049
304,468
199,781
202,298
16,649
22,862
7,121
15,217
21,901
29,322
35,040
37,830
41,288
21,407
22,890
19,862
20,791
21,740
11,271
11,298
15,648
9,053
9,512
9,300
9,010
8,734
15,510
12,554
12,403
12,070
6,478
6,237
6,004
5,824
48,232
48,292
48,246
47,963
47,754
47,470
47,224
47,22447,47047,75447,96348,24648,29248,2325,8246,0046,2376,47812,07012,40312,55415,5108,7349,0109,3009,5129,05315,64811,29811,27121,74020,79119,86222,89021,40741,28837,83035,04029,32221,90115,2177,12122,86216,649202,298199,781304,468317,049336,946343,209354,538386,699444,843488,857515,080535,790533,142332,749337,675331,094331,906349,253353,350364,865357,889420,357423,518355,431368,809403,830384,375516,119356,816650,861716,628722,584719,223722,410738,693738,397728,124728,566623,787633,912620,375610,747578,721572,543557,426549,676143,690135,182135,792130,252136,528
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
363,139
333,165
165,261
127,150
132,203
280,674
198,643
201,257
15,747
22,862
7,121
15,217
21,901
29,322
35,040
35,287
39,606
20,559
11,779
9,779
11,509
13,130
7,909
8,360
14,833
7,904
7,572
7,360
7,070
6,794
14,540
11,584
11,433
11,100
5,993
6,237
6,004
5,824
48,232
48,292
48,246
47,963
47,754
47,470
47,224
47,22447,47047,75447,96348,24648,29248,2325,8246,0046,2375,99311,10011,43311,58414,5406,7947,0707,3607,5727,90414,8338,3607,90913,13011,5099,77911,77920,55939,60635,28735,04029,32221,90115,2177,12122,86215,747201,257198,643280,674132,203127,150165,261333,165363,1390000000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22,360
24,224
103,516
113,645
77,146
79,987
78,128
79,711
74,052
46,845
48,614
50,440
365,203
399,180
408,594
397,530
369,938
317,867
304,995
104,324
46,214
59,441
140,946
77,348
121,742
11,456
21,691
6,520
14,863
21,477
28,993
34,562
34,804
38,993
20,255
11,672
9,735
11,231
12,896
7,639
8,079
11,206
4,320
7,478
7,240
6,966
6,726
6,500
3,558
3,367
10,016
5,446
5,144
5,909
5,311
48,142
48,187
48,191
47,891
47,641
47,429
46,794
46,79447,42947,64147,89148,19148,18748,1425,3115,9095,1445,44610,0163,3673,5586,5006,7266,9667,2407,4784,32011,2068,0797,63912,89611,2319,73511,67220,25538,99334,80434,56228,99321,47714,8636,52021,69111,456121,74277,348140,94659,44146,214104,324304,995317,867369,938397,530408,594399,180365,20350,44048,61446,84574,05279,71178,12879,98777,146113,645103,51624,22422,36000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
141,983
127,815
141,529
123,907
66,360
53,866
57,903
65,190
62,770
70,082
61,899
53,670
51,783
35,381
28,775
31,170
35,584
41,083
25,250
58,188
78,480
69,705
137,492
119,391
77,566
3,001
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000003,00177,566119,391137,49269,70578,48058,18825,25041,08335,58431,17028,77535,38151,78353,67061,89970,08262,77065,19057,90353,86666,360123,907141,529127,815141,98300000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,543
1,682
848
11,111
10,083
9,282
8,610
3,362
2,938
4,315
4,649
0
0
0
0
970
970
970
970
485
970
0
0
31
65
0
0
28
0
0
00280065310097048597097097097000004,6494,3152,9383,3628,6109,28210,08311,1118481,6822,5430000000000000000000000000000000000000000000000000000000000
       Other Current Assets 
458
2,270
4,400
2,507
3,307
2,837
2,973
4,959
4,504
4,175
5,106
3,848
2,474
16,089
18,007
15,998
20,798
11,994
15,279
17,485
17,760
7,733
7,340
8,322
6,211
5,890
9,812
7,637
6,918
6,401
7,966
6,272
6,155
5,281
8,116
7,234
7,626
7,670
4,090
5,221
4,387
5,916
4,589
4,189
2,920
2,749
2,456
3,057
2,236
1,904
1,949
1,290
1,171
601
354
424
329
478
483
613
304
107
44
278
234
270
281
127
84
2,034
2,060
104
68
8,040
8,026
8,066
1,084
547
123
95
513
90
105
55
72
85
41
430
4304185725510590513951235471,0848,0668,0268,040681042,0602,03484127281270234278441073046134834783294243546011,1711,2901,9491,9042,2363,0572,4562,7492,9204,1894,5895,9164,3875,2214,0907,6707,6267,2348,1165,2816,1556,2727,9666,4016,9187,6379,8125,8906,2118,3227,3407,73317,76017,48515,27911,99420,79815,99818,00716,0892,4743,8485,1064,1754,5044,9592,9732,8373,3072,5074,4002,270458
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,560
21,373
177,948
209,796
184,846
23,794
1,138
1,041
902
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,940
1,940
0
970
970
970
485
0
0
0
0
0
0
0
0
0
0
000000000048597097097001,9401,94000000000000000000009021,0411,13823,794184,846209,796177,94821,37323,5600000000000000000000000000000000000000000000
       Property Plant Equipment 
1,761
1,789
1,821
1,939
2,336
3,420
4,505
6,608
8,909
10,102
10,552
26,621
27,564
32,593
33,252
33,315
34,178
34,859
34,468
34,152
33,518
33,214
35,008
36,067
37,576
39,491
44,446
48,150
44,790
45,312
45,269
45,012
45,006
44,585
43,386
42,053
40,623
39,237
25,406
23,177
22,116
21,574
20,223
19,485
18,065
16,802
15,506
14,240
13,323
1,138
1,041
902
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000009021,0411,13813,32314,24015,50616,80218,06519,48520,22321,57422,11623,17725,40639,23740,62342,05343,38644,58545,00645,01245,26945,31244,79048,15044,44639,49137,57636,06735,00833,21433,51834,15234,46834,85934,17833,31533,25232,59327,56426,62110,55210,1028,9096,6084,5053,4202,3361,9391,8211,7891,761
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
150,841
150,782
150,985
150,985
150,985
150,985
150,985
150,985
150,985
150,985
150,985
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000000000000000000150,985150,985150,985150,985150,985150,985150,985150,985150,985150,782150,84100000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,316
2,743
160,779
194,038
170,450
10,299
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,940
1,940
1,940
1,940
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000001,9401,9401,9401,9400000000000000000000010,299170,450194,038160,7792,7433,3160000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
381,740
367,230
362,960
358,483
354,006
349,529
345,052
340,573
336,061
331,602
327,127
67,131
65,112
63,093
78,510
75,910
73,309
70,723
68,141
65,559
66,077
63,366
60,654
57,941
55,227
52,514
49,801
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000049,80152,51455,22757,94160,65463,36666,07765,55968,14170,72373,30975,91078,51063,09365,11267,131327,127331,602336,061340,573345,052349,529354,006358,483362,960367,230381,74000000000000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
759
565
367
252
156
172
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
970
970
970
485
0
0
0
0
0
0
0
0
0
0
000000000048597097097000000000000000000000000001721562523675657590000000000000000000000000000000000000000000
> Total Liabilities 
14,992
9,290
11,868
7,737
8,554
410,687
413,647
418,435
414,779
420,252
414,667
445,718
427,528
436,982
433,973
441,393
435,890
433,319
428,766
433,408
429,926
447,359
418,139
564,578
428,729
460,271
424,291
412,206
389,872
383,784
317,776
324,039
315,152
307,592
281,545
281,217
284,272
279,466
164,977
164,590
164,416
157,000
153,383
151,245
152,798
146,028
139,800
125,530
124,753
122,313
122,842
2,600
3,083
1,866
1,444
1,263
1,102
5,437
1,060
22,828
4,761
4,801
256
150
163
940
322
487
371
368
468
379
623
517
585
455
5,753
423
424
427
654
412
461
434
42,355
42,886
43,424
377
37743,42442,88642,3554344614126544274244235,7534555855176233794683683714873229401631502564,8014,76122,8281,0605,4371,1021,2631,4441,8663,0832,600122,842122,313124,753125,530139,800146,028152,798151,245153,383157,000164,416164,590164,977279,466284,272281,217281,545307,592315,152324,039317,776383,784389,872412,206424,291460,271428,729564,578418,139447,359429,926433,408428,766433,319435,890441,393433,973436,982427,528445,718414,667420,252414,779418,435413,647410,6878,5547,73711,8689,29014,992
   > Total Current Liabilities 
13,551
8,172
10,756
6,447
7,271
9,410
12,378
17,172
13,523
19,700
14,141
45,218
27,054
36,533
25,306
31,433
30,147
31,664
27,359
32,255
29,027
37,854
21,775
164,408
28,465
59,885
27,938
27,535
111,707
105,482
39,139
45,232
36,228
36,094
27,481
26,906
29,740
24,997
26,328
25,901
25,919
18,387
14,529
12,480
14,766
15,264
12,970
124,890
124,301
122,313
122,842
2,600
2,487
1,308
932
796
680
5,056
709
22,506
4,761
4,801
256
150
163
940
322
487
371
368
468
379
623
517
585
455
5,753
423
424
427
654
412
461
434
377
403
410
377
3774104033774344614126544274244235,7534555855176233794683683714873229401631502564,8014,76122,5067095,0566807969321,3082,4872,600122,842122,313124,301124,89012,97015,26414,76612,48014,52918,38725,91925,90126,32824,99729,74026,90627,48136,09436,22845,23239,139105,482111,70727,53527,93859,88528,465164,40821,77537,85429,02732,25527,35931,66430,14731,43325,30636,53327,05445,21814,14119,70013,52317,17212,3789,4107,2716,44710,7568,17213,551
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
115,849
115,849
115,849
115,849
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000115,849115,849115,849115,84900000000000000000000000000000000000000000000000
       Accounts payable 
2,300
2,465
2,945
2,986
3,476
4,670
3,606
3,657
4,618
4,526
4,837
14,192
8,289
12,809
8,124
7,772
8,001
8,663
9,169
8,614
10,821
9,874
4,173
5,545
9,570
24,918
11,852
9,004
7,027
9,441
5,545
7,298
6,510
4,443
7,843
5,572
6,007
4,265
4,213
5,335
3,438
4,192
1,405
12,480
14,766
15,264
12,970
9,041
8,452
6,464
6,993
2,600
2,487
1,308
932
796
680
5,056
709
22,506
209
295
256
150
163
940
322
487
371
368
468
379
623
517
585
455
5,753
423
424
427
654
412
461
434
331
331
331
331
3313313313314344614126544274244235,75345558551762337946836837148732294016315025629520922,5067095,0566807969321,3082,4872,6006,9936,4648,4529,04112,97015,26414,76612,4801,4054,1923,4385,3354,2134,2656,0075,5727,8434,4436,5107,2985,5459,4417,0279,00411,85224,9189,5705,5454,1739,87410,8218,6149,1698,6638,0017,7728,12412,8098,28914,1924,8374,5264,6183,6573,6064,6703,4762,9862,9452,4652,300
       Other Current Liabilities 
11,251
5,707
7,811
3,461
3,795
4,740
8,772
13,515
8,905
15,174
9,304
31,026
18,765
21,450
17,182
23,661
22,146
23,001
18,190
23,641
18,206
27,980
17,602
21,282
18,895
34,967
16,086
18,531
22,759
23,650
21,073
25,413
29,718
28,701
19,638
21,334
23,733
20,732
22,115
20,566
22,481
14,195
13,124
11,050
14,009
13,692
11,072
8,425
7,394
5,688
6,320
2,004
2,286
1,215
744
539
529
381
468
22,458
4,552
4,506
256
150
163
170
188
124
158
143
155
126
90
0
0
0
5,306
18
0
0
0
18
0
0
0
11
0
0
001100018000185,306000901261551431581241881701631502564,5064,55222,4584683815295397441,2152,2862,0046,3205,6887,3948,42511,07213,69214,00911,05013,12414,19522,48120,56622,11520,73223,73321,33419,63828,70129,71825,41321,07323,65022,75918,53116,08634,96718,89521,28217,60227,98018,20623,64118,19023,00122,14623,66117,18221,45018,76531,0269,30415,1748,90513,5158,7724,7403,7953,4617,8115,70711,251
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
138,765
138,032
130,764
126,830
640
452
0
0
0
596
558
512
467
422
0
351
322
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
40,460
40,966
41,472
41,978
42,483
43,014
0
043,01442,48341,97841,47240,96640,4600000000000000000000003223510422467512558596000452640126,830130,764138,032138,7650000000000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
134,499
134,499
129,499
125,749
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000125,749129,499134,499134,4990000000000000000000000000000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
40,460
40,966
41,472
0
0
0
0
000041,47240,96640,460000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,266
3,533
1,265
1,081
640
452
0
0
0
596
558
512
467
422
0
351
322
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000032235104224675125585960004526401,0811,2653,5334,2660000000000000000000000000000000000000000000
> Total Stockholder Equity
121,536
120,962
123,924
127,445
135,136
138,989
143,779
154,108
163,942
190,495
205,708
188,194
196,259
291,584
294,151
297,004
302,803
289,091
290,457
289,176
286,702
203,502
0
0
0
0
0
0
33,646
36,573
40,113
40,826
38,198
41,661
50,361
49,877
53,403
53,283
368,165
371,200
350,664
331,857
291,460
235,454
201,740
197,181
197,146
191,519
179,715
77,468
79,456
14,049
19,779
5,255
13,773
20,638
28,220
29,603
36,770
18,460
16,646
18,089
19,606
20,641
21,577
10,331
10,976
15,161
8,682
9,144
8,832
8,631
8,111
14,993
11,969
11,948
6,317
6,055
5,813
5,577
5,170
47,820
47,831
47,812
5,608
4,868
4,046
46,847
46,8474,0464,8685,60847,81247,83147,8205,1705,5775,8136,0556,31711,94811,96914,9938,1118,6318,8329,1448,68215,16110,97610,33121,57720,64119,60618,08916,64618,46036,77029,60328,22020,63813,7735,25519,77914,04979,45677,468179,715191,519197,146197,181201,740235,454291,460331,857350,664371,200368,16553,28353,40349,87750,36141,66138,19840,82640,11336,57333,646000000203,502286,702289,176290,457289,091302,803297,004294,151291,584196,259188,194205,708190,495163,942154,108143,779138,989135,136127,445123,924120,962121,536
   Common Stock
406
408
414
417
419
420
422
430
430
430
430
434
435
435
437
438
438
438
438
439
439
442
437
438
439
440
441
441
441
442
447
448
449
450
451
454
454
453
587
607
597
588
551
506
483
483
483
475
452
437
437
437
441
441
441
441
441
441
441
441
441
441
441
439
441
441
441
441
441
442
442
442
442
442
442
442
442
442
442
442
442
742
742
742
742
742
742
742
742742742742742742742442442442442442442442442442442442442441441441441441439441441441441441441441441441441441437437437452475483483483506551588597607587453454454451450449448447442441441441440439438437442439439438438438438437435435434430430430430422420419417414408406
   Retained Earnings Total Equity0000-71,396-71,377-71,388-70,962-70,555-70,319-70,077-69,815-69,490-69,469-69,098-75,980-75,460-75,259-74,947-75,409-75,562-79,747-80,392-75,778-76,714-77,749-79,266-91,763-89,949-93,730-100,903-106,703-114,293-121,174-129,698-135,177-140,739-145,456-147,848-142,690-146,865-146,136-145,065-140,044-130,9390000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
365,331
341,207
341,760
342,224
337,407
321,840
224,796
224,436
154,354
154,515
134,512
134,506
134,490
134,482
130,065
130,059
107,968
107,968
96,914
96,914
96,916
96,914
90,282
90,282
90,282
83,650
83,649
83,649
83,649
83,649
83,649
80,996
80,996
75,690
75,690
75,690
75,690
75,690
78,006
77,500
76,994
0
0
0
0
000076,99477,50078,00675,69075,69075,69075,69075,69080,99680,99683,64983,64983,64983,64983,64983,65090,28290,28290,28296,91496,91696,91496,914107,968107,968130,059130,065134,482134,490134,506134,512154,515154,354224,436224,796321,840337,407342,224341,760341,207365,3310000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
556
94
3
575
502
113
83
39
-3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000-339831135025753945560000000000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.